# A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

> **NCT07751341** · PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-9839(sc) for Injection
- **DRUG:** SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion

## Key facts

- **NCT ID:** NCT07751341
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-07
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751341, "A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07751341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*